Current Report Filing (8-k)
October 01 2015 - 3:14PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of Earliest event Reported): September 28, 2015
TARGETED
MEDICAL PHARMA, INC.
(Exact
name of registrant as specified in its charter)
DELAWARE |
|
000-53071 |
|
20-5863618 |
(State or other jurisdiction of |
|
(Commission |
|
(IRS Employer |
incorporation or organization) |
|
File Number) |
|
Identification No.) |
2980
BEVERLY GLEN CIRCLE, SUITE 301
LOS
ANGELES, CA 90077
(Address
of principal executive offices)
(310)
474-9808
(Registrant’s
telephone number, including area code)
Not
Applicable
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
[ ] |
Written communications pursuant to Rule 425
under the Securities Act (17 CFR 230.425) |
|
|
[ ] |
Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12) |
|
|
[ ] |
Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
[ ] |
Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c)) |
Item
4.01 Changes in Registrant’s Certifying Accountant.
On
September 29, 2015, Targeted Medical Pharma, Inc., a Delaware corporation (the “Company”), dismissed the Company’s
independent registered public accounting firm, Marcum LLP (“Marcum”) effective immediately. The decision to dismiss
Marcum was approved by the Audit Committee of the Board of Directors (the “Audit Committee”) of the Company on September
28, 2015.
In
connection with the audits of the fiscal years ended December 31, 2014 and 2013 and through September 28, 2015, there were (i)
no disagreements with Marcum on any matter of accounting principles or practices, financial statement disclosure, or auditing
scope or procedure, which disagreements if not resolved to the satisfaction of Marcum would have caused them to make reference
to the subject matter of the disagreement(s) in connection with their report; (2) no “reportable events” as such term
is defined in Item 304(a)(1)(v) of Regulation S-K.
Marcum’s
report on the financial statements of the Company for the years ended December 31, 2014 and 2013 did not contain an adverse opinion
or a disclaimer of opinion, nor was it qualified or modified as to uncertainty, audit scope, or accounting principles except that
both reports stated there is substantial doubt about the Company’s ability to continue as a going concern due to the Company’s
financial condition as of December 31, 2014 and December 31, 2013.
The
Company has provided Marcum with a copy of this Form 8-K prior to its filing with the Securities and Exchange Commission (the
“SEC”), and has requested that Marcum furnish a letter addressed to the SEC stating whether it agrees with the above
statements and, if not, stating the respects in which it does not agree. A copy of such letter, dated October 1, 2015, indicating
that it is in agreement with such disclosures is filed as Exhibit 16.1 to this Form 8-K.
On
September 29, 2015, the Company engaged Squar Milner, LLP as the Company’s independent registered public accounting firm
effective immediately. The engagement was approved by the Audit Committee on September 28, 2015. Prior to September 28, 2015,
neither the Company nor anyone acting on its behalf consulted with Squar Milner, LLP regarding (1) the application of accounting
principles to a specified transaction, either completed or proposed, (2) the type of audit opinion that might be rendered on the
Company’s financial statements, (3) written or oral advice provided that would be an important factor considered by the
Company in reaching a decision as to an accounting, auditing or financial reporting issue, or (4) any matter that was the subject
of a disagreement between the Company and its predecessor auditor as described in Item 304(a)(1)(iv) or a reportable event as
described in Item 304(a)(1)(v) of Regulation S-K.
The
Company has authorized Marcum to respond fully to any inquiries of Squar Milner, LLP.
Item
9.01 Financial Statements and Exhibits.
(d) Exhibits
The following
exhibits are filed with this Current Report on Form 8-K:
Exhibit
No. |
|
Description |
|
|
|
16.1 |
|
Letter to the
Securities and Exchange Commission from Marcum LLP dated October 1, 2015. |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Dated: October
1, 2015
|
TARGETED MEDICAL PHARMA, INC. |
|
|
|
|
By: |
/s/ William
B. Horne |
|
Name: |
William B. Horne |
|
|
Chief Financial Officer |
October
1, 2015
Securities
and Exchange Commission
100 F Street,
N.E.
Washington,
Dc 20549
Commissioners:
We have
read the statements made by Targeted Medical Pharma, Inc. under Item 4.01 of its Form 8-K dated October 1, 2015. We agree with
the statements concerning our Firm in such Form 8-K; we are not in a position to agree or disagree with other statements of Targeted
Medical Pharma, Inc. contained therein.
Very
truly yours, |
|
|
|
Marcum
LLP |
|
Targeted Medical Pharma (CE) (USOTC:TRGM)
Historical Stock Chart
From Jul 2024 to Aug 2024
Targeted Medical Pharma (CE) (USOTC:TRGM)
Historical Stock Chart
From Aug 2023 to Aug 2024